Regulatory ApprovalThe feedback from FDA supports a single Phase 3 for full approval based on events relating to disease progression, with no biopsy endpoint, which is seen as a favorable result.
Research And DevelopmentPhase 2 SPRING data is being highlighted at conferences, indicating progress in their research and development.
Strategic PartnershipsChemomab is in active strategic partnering discussions to advance the program into Phase 3, which is expected to bring the asset forward significantly.